BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Annovis Bio (NYSE American: ANVS) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Annovis Bio (NYSE American: ANVS)
 's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06709014-738@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Buntanetap: Phase 3 readout est. (NCT06709014)
DESCRIPTION:Buntanetap\, phase 3\, Alzheimer's Disease.\nStudy: A Double-bl
 ind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants
  With Early AD\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/buntanetap#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06709014
URL:https://assetmemo.bio/drug/buntanetap#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284784-738@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Buntanetap: Phase 2/3 readout est. (NCT07284784)
DESCRIPTION:Buntanetap\, phase 2/3\, Parkinson's Disease.\nStudy: A Study o
 f Buntanetap in Participants With PD\nEstimated primary completion: Septem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/buntanetap#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0728
 4784
URL:https://assetmemo.bio/drug/buntanetap#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757204-738@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20300221
DTEND;VALUE=DATE:20300222
SUMMARY:Buntanetap: Phase 2/3 readout est. (NCT07757204)
DESCRIPTION:Buntanetap\, phase 2/3.\nStudy: An Open-label Long-term Safety 
 Study of Buntanetap in Participants With AD\nEstimated primary completion:
  21 February 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bu
 ntanetap#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07757204
URL:https://assetmemo.bio/drug/buntanetap#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
